{"pii": "S2372770522001061", "abstracts": {"#name": "abstracts", "$": {"xmlns:ce": true, "xmlns:dm": true, "xmlns:sb": true}, "$$": [{"#name": "attachments", "$$": [{"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S2372770522001061-fx1.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2372770522001061/fx1/DOWNSAMPLED/image/jpeg/ab07aa9b25d3f783d91adeaf2789e830/fx1.jpg"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "28668"}, {"#name": "pixel-height", "_": "375"}, {"#name": "pixel-width", "_": "375"}, {"#name": "attachment-type", "_": "IMAGE-DOWNSAMPLED"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S2372770522001061-fx1.sml"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2372770522001061/fx1/THUMBNAIL/image/gif/f9444f7ca94d08172f1b3bebd53e8c84/fx1.sml"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1.sml"}, {"#name": "extension", "_": "sml"}, {"#name": "filesize", "_": "7193"}, {"#name": "pixel-height", "_": "164"}, {"#name": "pixel-width", "_": "164"}, {"#name": "attachment-type", "_": "IMAGE-THUMBNAIL"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S2372770522001061-fx1_lrg.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S2372770522001061/HIGHRES/image/jpeg/d16df8762aecb85528e147af08f2484c/fx1_lrg.jpg"}, {"#name": "file-basename", "_": "fx1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "fx1_lrg.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "130505"}, {"#name": "pixel-height", "_": "996"}, {"#name": "pixel-width", "_": "996"}, {"#name": "attachment-type", "_": "IMAGE-HIGH-RES"}]}]}, {"#name": "abstract", "$": {"id": "abs0010", "view": "all", "class": "author"}, "$$": [{"#name": "abstract-sec", "$": {"id": "abssec0010", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0010", "view": "all"}, "$$": [{"#name": "__text__", "_": "Tripartite motif 22 (TRIM22) is an agonist of nuclear factor \u03baB (NF-\u03baB) that plays an important role in the proliferation and drug sensitivity of glioblastoma (GBM). However, the molecular mechanism underlying the protein network between TRIM22 and nuclear factor \u03baB (NF-\u03baB) in GBM remains unclear. Here, we found that knockout of "}, {"#name": "italic", "_": "TRIM22"}, {"#name": "__text__", "_": " effectively inhibited tumor proliferation and increased the sensitivity of GBM cells to temozolomide (TMZ) "}, {"#name": "italic", "_": "in\u00a0vivo"}, {"#name": "__text__", "_": " and "}, {"#name": "italic", "_": "in\u00a0vitro"}, {"#name": "__text__", "_": ". Moreover, TRIM22 forms a complex with cytosolic purine 5-nucleotidase (NT5C2) in GBM and regulates the ubiquitination of retinoic acid-inducible gene-I (RIG-I). TRIM22 promotes the K63-linked ubiquitination of RIG-I, while NT5C2 is responsible for K48-linked ubiquitination. This regulation directly affects the RIG-I/NF-\u03baB/cell division cycle and apoptosis regulator protein 1 (CCAR1) signaling axis. Ubiquitin modification inhibitor of RIG-I restores the inhibition of tumor growth induced by "}, {"#name": "italic", "_": "TRIM22"}, {"#name": "__text__", "_": " knockout. The follow-up results showed that compared with patients with high TRIM22 expression, patients with low TRIM22 expression had a longer survival time and were more sensitive to treatment with TMZ. Our results revealed that the TRIM22-NT5C2 complex orchestrates the proliferation of GBM and benefits of TMZ through post-translational modification of RIG-I and the regulation of the RIG-I/NF-\u03baB/CCAR1 pathway and is a promising target for single-pathway multi-target therapy."}]}]}]}, {"#name": "abstract", "$": {"class": "graphical", "id": "abs0015", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0010"}, "_": "Graphical abstract"}, {"#name": "abstract-sec", "$": {"id": "abssec0015", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0015", "view": "all"}, "$$": [{"#name": "display", "$$": [{"#name": "figure", "$": {"id": "undfig1"}, "$$": [{"#name": "link", "$": {"xmlns:xlink": true, "locator": "fx1", "type": "simple", "href": "pii:S2372770522001061/fx1", "id": "aep-link-id8"}}]}]}]}]}]}, {"#name": "abstract", "$": {"class": "teaser", "id": "abs0020", "view": "all"}, "$$": [{"#name": "abstract-sec", "$": {"id": "abssec0020", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0020", "view": "all"}, "_": "TRIM22-NT5C2 complex orchestrates the proliferation of GBM and is sensitive to TMZ through post-translational modification of RIG-I. The discovery of the TRIM22-NT5C2/RIG-I/NF-kB/CCAR1 pathway offers new hope for multi-target combination therapy for GBM and improves the drug resistance of gliomas to TMZ."}]}]}]}}